<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043026</url>
  </required_header>
  <id_info>
    <org_study_id>UoL001456 - 4843</org_study_id>
    <nct_id>NCT04043026</nct_id>
  </id_info>
  <brief_title>The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function</brief_title>
  <acronym>RALiC</acronym>
  <official_title>Stratifying Clinical Risk in Patients With Atrial Fibrillation and Chronic Kidney Disease by Studying How Abnormalities in Clot Structure/Function and Lipoproteins Contribute to Thrombosis and Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Liverpool Centre for Cardiovascular Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool Heart and Chest Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool John Moores University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the role of lipids/lipoproteins as a potential cause&#xD;
      for the harmful changes seen in fibrin clot properties with renal dysfunction and atrial&#xD;
      fibrillation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational, blinded study that will be conducted in two parts. The&#xD;
      first study will assess the relationship between lipids/lipoproteins and fibrin clot&#xD;
      properties among anticoagulated atrial fibrillation patients with and without renal&#xD;
      dysfunction. The second study will assess the effects of statin therapy on&#xD;
      lipids/lipoproteins and fibrin clot properties in anticoagulated atrial fibrillation patients&#xD;
      with renal dysfunction. Renal dysfunction is defined as an estimated glomerular filtration&#xD;
      rate below 50 ml/min/1.73m2 for the purposes for this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">August 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>WP1: Fibrin clot structure and function assessment using validated turbidity and fibrinolysis test</measure>
    <time_frame>At baseline</time_frame>
    <description>Lag time, maximum absorbance, time to maximum absorbance and clot lysis time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP1: Fibrin permeation analysis using validated test</measure>
    <time_frame>At baseline</time_frame>
    <description>Permeation constant (Ks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP1: Low density lipoprotein fractions</measure>
    <time_frame>At baseline</time_frame>
    <description>Measure of low density lipoprotein subclass fractions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP1: Oxidised low density lipoprotein</measure>
    <time_frame>At baseline</time_frame>
    <description>Measure of oxidised low density lipoprotein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP2: Fibrin clot structure and function assessment using validated turbidity and fibrinolysis test</measure>
    <time_frame>At baseline and after 6 weeks of statin therapy</time_frame>
    <description>Lag time, maximum absorbance, time to maximum absorbance and clot lysis time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP2: Fibrin permeation analysis using validated test</measure>
    <time_frame>At baseline and after 6 weeks of statin</time_frame>
    <description>Permeation constant (Ks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP2: Low density lipoprotein fractions</measure>
    <time_frame>At baseline and after 6 weeks of statin</time_frame>
    <description>Measure of low density lipoprotein subclass fractions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP2: Oxidised low density lipoprotein</measure>
    <time_frame>At baseline and after 6 weeks of statin</time_frame>
    <description>Measure of oxidised low density lipoprotein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WP1: Scanning electron microscopy</measure>
    <time_frame>At baseline</time_frame>
    <description>Qualitative assessment of fibril indices</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>WP1: AF + CKD</arm_group_label>
    <description>Anticoagulated participants with atrial fibrillation and chronic kidney disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP1: AF + no CKD</arm_group_label>
    <description>Anticoagulated participants with atrial fibrillation and no chronic kidney disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP1: no AF + CKD</arm_group_label>
    <description>Anticoagulated participants with chronic kidney disease and no atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP1: no AF + no CKD</arm_group_label>
    <description>Anticoagulated participants without atrial fibrillation or chronic kidney disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP2: AF + CKD</arm_group_label>
    <description>Anticoagulated participants with atrial fibrillation and chronic kidney disease, and are commencing statin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Any statin therapy</description>
    <arm_group_label>WP2: AF + CKD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from the hospital and specialist clinics in the community&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        6.1 Inclusion criteria&#xD;
&#xD;
        WP1:&#xD;
&#xD;
          -  On anticoagulation therapy&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
        WP2:&#xD;
&#xD;
          -  Not receiving statins prior to recruitment&#xD;
&#xD;
          -  Diagnosed atrial fibrillation&#xD;
&#xD;
          -  On anticoagulation therapy&#xD;
&#xD;
          -  Estimated glomerular filtration rate of &lt;50 ml/min/1.73m2&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
        6.2 Exclusion criteria&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Severe mitral stenosis or presence of metallic prosthetic valve&#xD;
&#xD;
          -  Active or recent malignancy (&lt;6 months)&#xD;
&#xD;
          -  Active immunological disease&#xD;
&#xD;
          -  Connective tissue disease&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Recent or chronic serious infection&#xD;
&#xD;
          -  Chronic inflammatory disease&#xD;
&#xD;
          -  Known haemophilia or thrombophilia&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Untreated hypothyroidism or hyperthyroidism&#xD;
&#xD;
          -  Recent surgery (&lt;3 months)&#xD;
&#xD;
          -  Familial lipid disorders&#xD;
&#xD;
          -  Concurrent use of steroids&#xD;
&#xD;
          -  Dietary supplements known to influence lipids&#xD;
&#xD;
          -  Contraindications/inability/unwillingness to commence statin (WP2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wern Yew Ding</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wern Yew Ding</last_name>
    <phone>0151 794 9020</phone>
    <email>wding@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Wilkinson</last_name>
      <phone>00441516001467</phone>
      <email>Vicky.Wilkinson@lhch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Rogers</last_name>
      <phone>00441517063320</phone>
      <email>heather.rogers@rlbuht.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Wern Yew Ding</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>Fibrin clot structure and function</keyword>
  <keyword>Lipids</keyword>
  <keyword>Lipoproteins</keyword>
  <keyword>Statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

